Chromocell Therapeutics Corporation (CHRO) - Total Assets
Based on the latest financial reports, Chromocell Therapeutics Corporation (CHRO) holds total assets worth $822.85K USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Chromocell Therapeutics Corporation net assets for net asset value and shareholders' equity analysis.
Chromocell Therapeutics Corporation - Total Assets Trend (2020–2024)
This chart illustrates how Chromocell Therapeutics Corporation's total assets have evolved over time, based on quarterly financial data.
Chromocell Therapeutics Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Chromocell Therapeutics Corporation's total assets of $822.85K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.5% |
| Accounts Receivable | $40.40K | 3.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Chromocell Therapeutics Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CHRO market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chromocell Therapeutics Corporation's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 37.5% of total assets in 2024, up from 0.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 3.0% of total assets.
Chromocell Therapeutics Corporation Competitors by Total Assets
Key competitors of Chromocell Therapeutics Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GlycoMimetics Inc
NASDAQ:GLYC
|
USA | $5.99 Billion |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $584.09 Million |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Chromocell Therapeutics Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 0.93 | 0.00 |
| Quick Ratio | 0.11 | 0.93 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.49 Million | $-182.52K | $-2.88 Million |
Chromocell Therapeutics Corporation - Advanced Valuation Insights
This section examines the relationship between Chromocell Therapeutics Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.11 |
| Latest Market Cap to Assets Ratio | 6.50 |
| Asset Growth Rate (YoY) | 1320.4% |
| Total Assets | $1.37 Million |
| Market Capitalization | $8.90 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Chromocell Therapeutics Corporation's assets at a significant premium (6.50x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Chromocell Therapeutics Corporation's assets grew by 1320.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Chromocell Therapeutics Corporation (2020–2024)
The table below shows the annual total assets of Chromocell Therapeutics Corporation from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.37 Million | +1320.41% |
| 2023-12-31 | $96.39K | 0.00% |
| 2023-09-30 | $96.39K | +75.02% |
| 2022-12-31 | $55.07K | 0.00% |
| 2022-09-30 | $55.07K | -- |
| 2021-12-31 | $0.00 | -- |
| 2021-09-30 | $0.00 | -- |
| 2020-12-31 | $71.87K | 0.00% |
| 2020-09-30 | $71.87K | -- |
About Chromocell Therapeutics Corporation
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and id… Read more